- 1. E-F1
- [Heterotrimeric Elongation Factor 1 (containing alpha/beta/gamma or alpha/delta/gamma subunits) is responsible for delivery of aminoacyl tRNAs to the ribosome. Containing domains that bind guanine nucleotides, 80S ribosomes, and aminoacyl-tRNAs, the alpha EF-1 subunit interacts with beta/delta subunits and mediates delivery and GTP-dependent binding of aminoacyl-tRNAs to the 80S ribosome A-site. Homologous beta and delta subunits (guanine nucleotide exchange factors) stimulate GDP/GTP exchange bound to EF-1-alpha; phosphorylation affects the GDP/GTP exchange rate. The conserved gamma subunit contains an EEF1G domain and an N-terminal GST domain that may be involved in regulating EF-1 multisubunit assembly and anchorage to other cellular components. (NCI) ( NCI )] (UMLS (NCI) C0059036) =Amino Acid, Peptide, or Protein; Enzyme
| - 27. Effects, unexpected therapeutic
- (UMLS (NCI) C0235735) =Finding
|
- 2. E2F Transcription Factor 1
- [Transcription factor E2F1 binds to DNA as homo or heterodimers with DP1 or DP2. It activates p53 and p73 gene expression. MYC-induced apoptosis involves E2F1. E2F1 can induce apoptosis in a p53-independent manner by accumulation of p73 or by a death receptor-dependent mechanism via down regulating TRAF2 and inhibiting activation of NFKB anti-apoptotic signals. E2F1 induces p53-dependent apoptosis by inducing ARF, which neutralizes MDM2 and stabilizes p53. E2F is a critical determinant of G1/S transition, activating transcription of genes necessary for DNA replication. RB interacts with E2F factors to arrest cells in G1 by active transcriptional repression. RB/E2F repression mediates G1 arrest triggered by TGFB, by p16(INK4A), and by contact inhibition. Accumulation of G1 cyclins E and D1 is regulated by E2F1. TCR-AICD, in a p53-independent late G1 phase cell-cycle checkpoint, is dependent on E2F1 and TP73. (from OMIM and NCI) ( NCI )] (UMLS (NCI) C1506928) E2F1;
E2F-1;
PBR3;
PRB-Binding Protein E2F-1;
RBAP-1;
RBBP-3;
Retinoblastoma Associated Protein 1;
Retinoblastoma Binding Protein 3;
Retinoblastoma-Associated Protein 1;
Transcription Factor E2F =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 28. Efferent Duct
- [One of 12 to 14 small seminal ducts leading from the testis to the head of the epididymis. ( NCI )] (UMLS (NCI) C0228013) =Body Part, Organ, or Organ Component
|
- 3. E2F Transcription Factor 1 Gene
- [This gene plays a regulatory role in G1/S cell cycle checkpoints and apoptosis. ( NCI )] (UMLS (NCI) C0812258) E2F1;
E2F1 Gene =Gene or Genome | - 29. efferent nerve
- [neurons which send impulses peripherally to activate muscles or secretory cells. ( CSP )] (UMLS (CSP) C0027884) =Cell ;
=nerve;
peripheral nervous system |
- 4. EF hand
- [Forming a single Ca2+-binding site in many calcium-binding proteins, the basic EF-Hand Domain consists of a conserved 12-residue loop region between two perpendicular 10-12 residue alpha helices (helix-loop-helix). Ca2+ interacts with loop residues in a pentagonal bipyramidal configuration; each loop residue is important for Ca2+ coordination. Loop residues 1, 3, 5, 7, 9, and 12 (invariant Glu or Asp) are directly necessary for Ca2+ binding. Amino-acid variations at positions 1, 3, 5, 7, and 9 alter ion affinity. Single or multiple domains cause structural/functional variations. EF-hand Proteins are grouped into either regulatory/signaling or structural/buffering/transport categories. Ca2+ binding to regulatory proteins induces conformational/functional change; Ca2+ binding to structural proteins seems to provide a Ca2+ buffer. (NCI) ( NCI )] (UMLS (CSP) C0752218) EF-Hand Calcium-Binding Motif;
EF-Hand Domain;
EF-Hand Motif =Spatial Concept | - 30. Efferent Pathway
- [Nerve structures through which impulses are conducted from a nerve center toward a peripheral site. (MeSH) ( NCI )] (UMLS (NCI) C0013681) =Body Part, Organ, or Organ Component
|
- 5. EFABP
- [Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI) ( NCI )] (UMLS (NCI) C1312695) Epidermal Fatty Acid-Binding Protein;
FABP5;
Fatty Acid Binding Protein 5;
PAFABP;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 31. Effervescent Granule Dosage Form
- [A small particle or grain containing a medicinal agent in a dry mixture usually composed of sodium bicarbonate, citric acid, and tartaric acid which, when in contact with water, has the capability to release gas, resulting in effervescence. ( NCI )] (UMLS (NCI) C1273633) Effervescent Granule Dose Form;
GRAN EFFRV;
GRANULE, EFFERVESCENT =Biomedical or Dental Material |
- 6. Efavirenz
- [antiHIV 1 agent; reverse transcriptase inhibitor; 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3,1-benzoxazin-2-one. ( CSP )] (UMLS (NCI) C0674428) =Organic Chemical; Pharmacologic Substance =[AM800] ANTIVIRALS;
oxazine;
Reverse Transcriptase Inhibitor;
L 743726 =EFAVIRENZ 100 MG;
EFAVIRENZ 50 MG;
EFAVIRENZ 200 MG;
EFAVIRENZ 600 MG | - 32. Effervescent Tablet Dosage Form
- [A solid dosage form containing mixtures of acids (e.g., citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration. (FDA) ( NCI )] (UMLS (NCI) C1273644) Effervescent Tablet Dose Form;
TAB EFFRV;
TABLET, EFFERVESCENT =Biomedical or Dental Material |
- 7. EFF HIGH ALTITUD NEC/NOS
- [ ] (UMLS (ICD9CM) C0029499) =Injury or Poisoning
| - 33. Effexor
- (UMLS (NCI) C0591437) =Organic Chemical; Pharmacologic Substance ;
|
- 8. Effect
- [A phenomenon that follows and is caused by some previous phenomenon. ( NCI )] (UMLS (NCI) C1280500) =Qualitative Concept
| - 34. Efficacy Lack
- [The lack of expected or desired effect related to a therapy. (NCI) ( NCI )] (UMLS (NCI) C0235828) =Finding
|
- 9. EFFECT AIR PRESSURE NEC
- [ ] (UMLS (ICD9CM) C0161747) =Injury or Poisoning
| - 35. effusion
- [A collection of fluid in a body cavity. It may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung). — 2003 ( NCI )] (UMLS (CSP) C0013687) =Pathologic Function
|
- 10. EFFECT AIR PRESSURE NOS
- [ ] (UMLS (ICD9CM) C0161748) =Injury or Poisoning
| - 36. Effusion
- (UMLS (HL7) C1546613) =Intellectual Product =Specimen Source Codes;
|
- 11. EFFECT EXTERNAL CAUS NEC
- (UMLS (ICD9CM) C0013679) =Injury or Poisoning
| - 37. Effusion of ankle and foot joint
- [ ] (UMLS (ICD9CM) C0158156) =Pathologic Function ;
|
- 12. Effect observed when patient receives placebo
- (UMLS (HL7) C1547001) =Idea or Concept =Causality Observations;
| - 38. Effusion of forearm joint
- [ ] (UMLS (ICD9CM) C0158152) =Pathologic Function ;
|
- 13. Effect prosthetic device
- (UMLS (ICPC) C0497149) (Effect prosthetic device; ONDORII BIGARRENDARRAK(EPA LUZERA) SINTESI,PROTESE MATERIA-LA,BIKG; Bivirkning ved hjaelpemidler; Gevolgen prothese/pacemaker; PROTEESIN VAIKUTUS; Effet secondaire prothese; Wirkung Prothese/Trans-/Implantat; (108); gyogyaszati segedeszkoz szovodm.; Conseguenze applicazione protesi; PLAGER MED PROTESE IKA; Efeito de protese; Ef dispositivos protesicos; INVERKAN AV IMPLANTAT/FRAMMANDE MATERIAL) =Finding =GENERAL AND UNSPECIFIED; Diagnosis/Diseases Component
| - 39. Effusion of hand joint
- [ ] (UMLS (ICD9CM) C0158153) =Pathologic Function ;
|
- 14. EFFECT REDUCED TEMP NEC
- [ ] (UMLS (ICD9CM) C0161738) =Injury or Poisoning
| - 40. Effusion of joint
- [Accumulation of watery fluid in the cavity of a joint. (Dorland, 27th ed) ( MSH )] (UMLS (ICD9CM) C1253936) Effusion of joint, site unspecified;
Hydrarthrosis;
Joint Effusion;
JOINT EFFUSION-UNSPEC =Disease or Syndrome =arthropathic;
|
- 15. EFFECT REDUCED TEMP NOS
- [ ] (UMLS (ICD9CM) C0161734) =Injury or Poisoning
| - 41. Effusion of joint of multiple sites
- [ ] (UMLS (ICD9CM) C0158158) =Pathologic Function
|
- 16. effector cell
- [A cell that performs a specific function in response to a stimulus; usually used to describe cells in the immune system. ( NCI )] (UMLS (NCI) C0312740) =Cell ;
| - 42. Effusion of joint of other specified sites
- [ ] (UMLS (ICD9CM) C0158157) =Sign or Symptom ;
|
- 17. EFFECTS ELECTRIC CURRENT
- [ ] (UMLS (ICD9CM) C0161752) =Injury or Poisoning
| - 43. Effusion of joint of pelvic region and thigh
- [ ] (UMLS (ICD9CM) C0554588) =Pathologic Function
|
- 18. Effects of air pressure
- [ ] (UMLS (ICD9CM) C1306873) =Injury or Poisoning ;
| - 44. Effusion of joint of shoulder region
- [ ] (UMLS (ICD9CM) C0158150) =Pathologic Function ;
|
- 19. EFFECTS OF FOREIGN BODY ENTERING THROUGH ORIFICE
- [ ] (UMLS (ICD9CM) C0178329) =Injury or Poisoning
| - 45. Effusion of lower leg joint
- [ ] (UMLS (ICD9CM) C0158155) =Pathologic Function ;
|
- 20. Effects of heat and light
- [ ] (UMLS (ICD9CM) C0274287) =Injury or Poisoning
| - 46. Effusion of upper arm joint
- [ ] (UMLS (ICD9CM) C0158151) =Pathologic Function ;
|
- 21. EFFECTS OF HUNGER
- [ ] (UMLS (ICD9CM) C0311274) =Injury or Poisoning
| - 47. Eflornithine/Sulindac
- (UMLS (NCI) C0879516) =Therapeutic or Preventive Procedure ;
|
- 22. EFFECTS OF LIGHTNING
- [Accidental injuries caused by brief high-voltage electrical discharges during thunderstorms. Cardiopulmonary arrest, coma and other neurologic symptoms, myocardial necrosis, and dermal burns are common. Prompt treatment of the acute sequelae, including cardiopulmonary resuscitation, is indicated for survival. ( MSH )] (UMLS (ICD9CM) C0023702) =Injury or Poisoning ;
=Electric Injuries;
| - 48. Eflornithine/Triamcinolone
- (UMLS (NCI) C0935891) =Therapeutic or Preventive Procedure
|
- 23. Effects of radiation, unspecified
- [The effects of ionizing and nonionizing radiation upon living organisms, organs and tissues, and their constituents, and upon physiologic processes. It includes the effect of irradiation on drugs and chemicals. ( MSH )] (UMLS (ICD9CM) C0034525) =Biologic Function
| - 49. Eformoterol
- [A long-acting beta-adrenergic receptor agonist with bronchodilator activity. Formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, thereby activating intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, relieve bronchospasms, improve mucociliary clearance and reduce mediator substance release from inflammatory cells, especially from mast cells. ( NCI )] (UMLS (NCI) C0060657) =Organic Chemical; Pharmacologic Substance ;
=[RE102] BRONCHODILATORS, SYMPATHOMIMETIC,INHALATION;
Unclassified Ingredients =Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, rel-,(E)-2-butenedioate(2:1)(salt);
|
- 24. EFFECTS OF THIRST
- (UMLS (ICD9CM) C0013680) =Disease or Syndrome
| - 50. EFP
- [Encoded by human ZNF147 Gene (TRIM Family, RING Finger Family), the ubiquitous 630-amino acid 71 kD cytoplasmic estrogen-responsive Zinc Finger Protein 147 has potential DNA-binding and dimerization-transactivation domains, which suggest that ZNF147 may act as a transcription factor similar to other TRIM family members. The TRIM motif includes three zinc-binding domains, a SPRY domain, a RING, a B-Box Type 1 and Type 2, and a coiled-coil region. Zinc Finger Protein 147 is a RING-finger-dependent ubiquitin ligase (E3) that targets proteolysis of 14-3-3-sigma, a negative cell cycle regulator that causes G2 arrest. Lack of EFP function results in 14-3-3-sigma accumulation; 14-3-3-sigma is a target for proteolysis by EFP, leading to cell proliferation. (from Swiss-Prot, LocusLink, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1384551) Estrogen-Responsive Finger Protein;
TRIM25;
Tripartite Motif Protein TRIM25;
Tripartite Motif-Containing 25;
Z147;
Zinc Finger Protein 147;
Zinc Finger Protein-147;
ZNF147;
=Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 25. Effects, Psychosocial
- [Having to do with the physical, psychological, cognitive, and social consequences of disease, including stigmatization of persons affected. ( NCI )] (UMLS (NCI) C1458132) Psychosocial Effect;
Psychosocial Effects;
Psychosocial Effects/Treatment;
Treatment/Psychosocial Effects =Finding ;
| - 51. Efudex
- (UMLS (NCI) C0699372) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 26. Effects, teratogenic
- (UMLS (NCI) C0232910) =Pathologic Function
| |
home
